1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Indonesia Pharmaceuticals and Healthcare Report Q2 2016

Indonesia Pharmaceuticals and Healthcare Report Q2 2016

  • February 2016
  • -
  • Business Monitor International
  • -
  • 131 pages

BMI View: The challenges facing domestic pharmaceutical firms in Indonesia will continue. While effortsto alleviate the country's reliance on pharmaceutical raw material imports are underway, these are unlikelyto have a substantial impact until 2017. Moreover, the ability of Indonesia's universal healthcare programmeto facilitate sales will be constrained by the country's medical services infrastructure, and low commodityprices will weigh on the economy and household purchasing power.

Headline Expenditure Projections

- Pharmaceuticals: IDR77,643bn (USD5.7bn) in 2015 to IDR85,550bn(USD5.9bn) in 2016; +10.2%growth in local currency terms and 3.2% in US dollar terms.

- Healthcare: IDR347,253bn (USD25bn) in 2015 to IDR387,513bn (USD27bn) in 2016; +11.6% growthin local currency terms and 4.6% in US dollar terms.

Table Of Contents

Indonesia Pharmaceuticals and Healthcare Report Q2 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Indonesia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Indonesia 2012-2020) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Indonesia 2012-2020) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Indonesia 2012-2020) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Indonesia 2012-2020) 19
Prescription Drug Market Forecast 20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Indonesia 2012-2020) 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Indonesia 2012-2020) 24
Generic Drug Market Forecast 25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Indonesia 2012-2020) 27
OTC Medicine Market Forecast 28
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Indonesia 2012-2020) 30
Pharmaceutical Trade Forecast 31
Table: Pharmaceutical Trade Data And Forecasts (Indonesia 2014-2020) 33
Table: Pharmaceutical Trade Data And Forecasts local currency (Indonesia 2014-2020) 33
Industry Risk/Reward Index 34
Asia Pacific Risk/Reward Index 34
Indonesia Risk/Reward Index 40
Rewards 40
Risks 40
Regulatory Review 42
Pharmaceutical Advertising 44
Regional Harmonisation 45
Intellectual Property Issues 46
Halal Medicine Regulations 47
Labelling Requirements 48
Compulsory Licensing 48
Counterfeit Drugs 49
Generic Drug Legislation 50
Pricing Regime 51
Reimbursement Regime 52
Industry Trends And Developments 53
Market Overview 53
Public Health Developments 54
Table: UN Millennium Development Goals For Indonesia 54
Healthcare System 55
Health Insurance 56
Table: Healthcare Resources (Indonesia 2010-2015) 58
Table: Healthcare Personnel (Indonesia 2010-2015) 59
Table: Healthcare Activity (Indonesia 2010-2015) 59
Research and Development 59
Clinical Trials 60
Epidemiology 62
Table: Estimated Number Of New Cases Of Cancer In Indonesia 64
Competitive Landscape 67
Research-Based Industry 67
Table: Selected List Of Pharmaceutical Business Areas With Restricted Conditions 68
Table: Multinational Market Activity 69
Generic Drugmakers 70
Pharmaceutical Wholesale 71
Pharmaceutical Retail 72
Company Profile 75
Bayer 75
Darya-Varia Group 78
GlaxoSmithKline 81
Indopharma 84
Kimia Farma 87
Merck and Co 92
Merck Group 95
Novartis 99
Pfizer 102
PT Biofarma 105
PT Kalbe Farma 109
Sanofi 114
Soho Group 117
Demographic Forecast 120
Demographic Outlook 120
Table: Population Headline Indicators (Indonesia 1990-2025) 121
Table: Key Population Ratios (Indonesia 1990-2025) 121
Table: Urban/Rural Population and Life Expectancy (Indonesia 1990-2025) 122
Table: Population By Age Group (Indonesia 1990-2025) 122
Table: Population By Age Group % (Indonesia 1990-2025) 123
Glossary 125
Methodology 127
Pharmaceutical Expenditure Forecast Model 127
Healthcare Expenditure Forecast Model 127
Notes On Methodology 128
Risk/Reward Index Methodology 129
Index Overview 130
Table: Pharmaceutical Risk/Reward Index Indicators 130
Indicator Weightings 131

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.